🇺🇸 FDA
Pipeline program

MEDI9929

D5240C00001

Phase 2 mab completed

Quick answer

MEDI9929 for Atopic Dermatitis is a Phase 2 program (mab) at MedImmune with 1 ClinicalTrials.gov record(s).

Program details

Company
MedImmune
Indication
Atopic Dermatitis
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials